Skip to content

The serum urate-lowering effect and safety profile of "Yellow-dragon Wonderful-Seed" formula in the treatment of gout:a randomised controlled trial

The serum urate-lowering effect and safety profile of "Yellow-dragon Wonderful-Seed" formula in the treatment of gout:a randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-12001933
Enrollment
Unknown
Registered
2012-02-10
Start date
2012-02-06
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gout

Interventions

TCM-treated ?group:"Yellow-dragon Wonderful-Seed" formula (+Gypsum)
TCM-treated ? group:"Yellow-dragon Wonderful-Seed" formula (-Gypsum)
allopurinol-treated group:allopurinol

Sponsors

Teaching Hospital of Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Physician diagnosis of gout; 2. Have hyperuricemia (serum urate > 7.0 mg/dl); 3. To be aged 18 years to 70 years; 4. Subjects receiving urate-lowering therapy will undergo a 2-week washout period. Only those whose sUA remain > 7.0 mg/dl after washout period will be included; 5. Sign the informed consent forms.

Exclusion criteria

Exclusion criteria: 1. Age 70 years; 2. Pregnancy or lactation; 3. Severe cardiovascular, brain, liver, kidney and hematopoietic system comorbidities; mental disorders; cancer; 4. Disabled subjects due to severe deforming gouty arthropathy; 5. Concurrent therapy with urate-lowering agents, azathioprine, 6-mercaptopurine, or medications containing aspirin (>325mg) or other salicylates; 6. Serum creatinine >1.5mg/dL or ALT more than doubles the upper limit of the normal range; 7. Arrythmia of clinical significance; 8. Allergic to allopurinol or Traditional Chinese Medicine used in the present study or allergic constitution; 9. A history of alcohol abuse; 10. Subjects participating other clinical trials within the past three months.

Design outcomes

Secondary

MeasureTime frame
scores on SF-36 scale;uric acid in urine;erythrocyte sedimentation rate (ESR);X ray;C-reactive protein;

Primary

MeasureTime frame
serum urat;

Countries

China

Contacts

Public ContactSen Zhong
zhongsen6606@163.com+86 18980086606

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 5, 2026